There was a possible trend toward higher activity in HPV + patients (ORR 50%) and evidence of clinical activity irrespective of PD-L1 status.
← all excerpts
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
1
—
—